Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions
End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights...
Uloženo v:
| Vydáno v: | Nephrology, dialysis, transplantation |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
13.11.2025
|
| Témata: | |
| ISSN: | 1460-2385, 1460-2385 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, an FDA-approved drug, as a potential osmotic agent.
To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were done using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6 J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers, and cardiac damage.
In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as IL-6 and VEGF-A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart, and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects.
Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease. |
|---|---|
| AbstractList | End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, an FDA-approved drug, as a potential osmotic agent.
To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were done using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6 J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers, and cardiac damage.
In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as IL-6 and VEGF-A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart, and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects.
Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease. End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, an FDA-approved drug, as a potential osmotic agent.BACKGROUND AND HYPOTHESISEnd-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and increased cardiovascular pathology. These complications can be exacerbated by exposure to PD solutions (PDS) containing glucose. This highlights the clinical unmet need for novel osmotic agents to replace glucose. Here, we tested troxerutin, an FDA-approved drug, as a potential osmotic agent.To evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were done using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6 J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers, and cardiac damage.METHODSTo evaluate troxerutin osmotic and non-toxic effects, in vitro and in vivo experiments were done using artificial membranes, mice and cultured human mesothelial cells (MCs). The local and systemic consequences of chronic peritoneal exposure to PDS associated to renal insufficiency were investigated in a preclinical model. 5/6 nephrectomized C57BL/6 J mice were daily exposed to glucose- or troxerutin-PDS for 60 days, then evaluating tissue damage, proinflammatory markers, and cardiac damage.In vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as IL-6 and VEGF-A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart, and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects.RESULTSIn vitro and in vivo studies revealed that troxerutin exhibits similar osmotic and ultrafiltration capacities to glucose, but with colloidal properties. Moreover, only glucose, but not troxerutin, reduced MC viability, induced mesothelial-to-mesenchymal transition, and increased damage markers (such as IL-6 and VEGF-A). In the preclinical model, long-term treatment with glucose-PDS, but not troxerutin-PDS, significantly increased peritoneal membrane thickening, tissue proinflammatory markers (evaluated in peritoneum, kidney, heart, and aorta) and cardiovascular damage (cardiac hypertrophy and fibrosis) in mice. These preclinical data clearly demonstrate the wide deleterious effects of chronic peritoneal exposure to glucose-containing PDS in mice with kidney insufficiency and that the replacement of glucose with troxerutin notably reduces these effects.Troxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease.CONCLUSIONTroxerutin emerges as a more biocompatible alternative to glucose as an osmotic agent for PD therapy, exhibiting no adverse local or systemic side effects in preclinical studies. This research presents a novel approach to reduce cardiovascular complications of PD in end-stage kidney disease. |
| Author | Strahl, Lisa Rodrigues-Diez, Raquel Cortés, Marcelino Piecha, Dorothea González-Mateo, Guadalupe T Eringa, Etto C Sucunza, David Ruiz-Ortega, Marta Toggweiler, Nora Vaquero, Juan J Kopytina, Valeria Kane, Jamie Tejera-Muñoz, Antonio Pascual-Antón, Lucía Marchant, Vanessa López-Cabrera, Manuel Vervloet, Marc |
| Author_xml | – sequence: 1 givenname: Valeria surname: Kopytina fullname: Kopytina, Valeria organization: Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Madrid, Spain – sequence: 2 givenname: Vanessa orcidid: 0000-0002-2767-0229 surname: Marchant fullname: Marchant, Vanessa organization: RICORS2040, Madrid, Spain – sequence: 3 givenname: Raquel surname: Rodrigues-Diez fullname: Rodrigues-Diez, Raquel organization: Physiology Department, Universidad Complutense de Madrid-CIBERCV, Madrid, Spain – sequence: 4 givenname: Lucía surname: Pascual-Antón fullname: Pascual-Antón, Lucía organization: Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Madrid, Spain – sequence: 5 givenname: Nora surname: Toggweiler fullname: Toggweiler, Nora organization: Fresenius Medical Care Deutschland GmbH, St. Wendel, Germany – sequence: 6 givenname: Lisa surname: Strahl fullname: Strahl, Lisa organization: Fresenius Medical Care Deutschland GmbH, St. Wendel, Germany – sequence: 7 givenname: Jamie surname: Kane fullname: Kane, Jamie organization: Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN, USA – sequence: 8 givenname: Antonio surname: Tejera-Muñoz fullname: Tejera-Muñoz, Antonio organization: Health Science Faculty-HM Hospitals, Camilo José Cela University, Madrid, Spain – sequence: 9 givenname: Marcelino surname: Cortés fullname: Cortés, Marcelino organization: Cardiology Department, Jiménez Díaz Foundation University Hospital, Madrid, Spain – sequence: 10 givenname: David surname: Sucunza fullname: Sucunza, David organization: Department of Organic and Inorganic Chemistry, Faculty of Pharmacy, University of Alcalá (IRYCIS), Alcalá de Henares, Spain – sequence: 11 givenname: Juan J surname: Vaquero fullname: Vaquero, Juan J organization: Department of Organic and Inorganic Chemistry, Faculty of Pharmacy, University of Alcalá (IRYCIS), Alcalá de Henares, Spain – sequence: 12 givenname: Marc orcidid: 0000-0003-4607-9415 surname: Vervloet fullname: Vervloet, Marc organization: Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands – sequence: 13 givenname: Dorothea surname: Piecha fullname: Piecha, Dorothea organization: Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany – sequence: 14 givenname: Etto C surname: Eringa fullname: Eringa, Etto C organization: Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands – sequence: 15 givenname: Marta surname: Ruiz-Ortega fullname: Ruiz-Ortega, Marta organization: RICORS2040, Madrid, Spain – sequence: 16 givenname: Manuel surname: López-Cabrera fullname: López-Cabrera, Manuel organization: Tissue and Organ Homeostasis Program, Cell-Cell Communication and Inflammation Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Madrid, Spain – sequence: 17 givenname: Guadalupe T surname: González-Mateo fullname: González-Mateo, Guadalupe T organization: Premium Research S.L., Guadalajara, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41231614$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtLAzEYxINU7ENP3iVHL2vz3t2jFF9Q8NL7kmeN7CY1yVb737uggqcZhh_zfcwSzEIMFoBrjO4wauk6mLLeO-kIa8_AAjOBKkIbPvvn52CZ8ztCqCV1fQHmDBOKBWYLoHYpftk0Fh-gz1DCEI-2hzEPsXgN5d6GAl1M8GCTL9Nh2UPjZX_KE_3pyxs8pFisLv5ooZbJ-HiUWY-9TFBOaQz5Epw72Wd79asrsHt82G2eq-3r08vmfltpTNq2kpJRiYQiSgglNGeSCUYJZ4oipbShreOIC4WEcdwZ1TircWMahmvcNJaswO1P7fTQx2hz6Qafte17GWwcc0dJjVtKecsn9OYXHdVgTXdIfpDp1P3NQr4BQnFoSQ |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025. Published by Oxford University Press on behalf of the ERA. |
| Copyright_xml | – notice: The Author(s) 2025. Published by Oxford University Press on behalf of the ERA. |
| DBID | NPM 7X8 |
| DOI | 10.1093/ndt/gfaf249 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2385 |
| ExternalDocumentID | 41231614 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 29M 2WC 4.4 482 48X 5RE 5VS 5WA 5WD 70D AABZA AACZT AAHTB AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPQP ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DILTD DU5 D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KOP KQ8 KSI KSN M-Z MHKGH N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SDH TCURE TEORI TJX TR2 WH7 WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 |
| ID | FETCH-LOGICAL-c1299-aa43a06b2b66b6c54a4643254b30bbcd39f5056b06df5fdb8fec18d8417188e2 |
| IEDL.DBID | 7X8 |
| ISSN | 1460-2385 |
| IngestDate | Fri Nov 14 18:48:17 EST 2025 Sat Nov 15 01:41:21 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | cardiovascular disease peritoneal dialysis osmotic agent biocompatibility kidney replacement therapy |
| Language | English |
| License | The Author(s) 2025. Published by Oxford University Press on behalf of the ERA. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1299-aa43a06b2b66b6c54a4643254b30bbcd39f5056b06df5fdb8fec18d8417188e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4607-9415 0000-0002-2767-0229 |
| OpenAccessLink | https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfaf249/65284769/gfaf249.pdf |
| PMID | 41231614 |
| PQID | 3271933595 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3271933595 pubmed_primary_41231614 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Nov-13 20251113 |
| PublicationDateYYYYMMDD | 2025-11-13 |
| PublicationDate_xml | – month: 11 year: 2025 text: 2025-Nov-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Nephrology, dialysis, transplantation |
| PublicationTitleAlternate | Nephrol Dial Transplant |
| PublicationYear | 2025 |
| SSID | ssj0009277 |
| Score | 2.481998 |
| SecondaryResourceType | online_first |
| Snippet | End-stage renal disease patients require peritoneal dialysis (PD) as a life-saving therapy; however, they continue to experience systemic inflammation and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | Troxerutin is a novel osmotic agent for peritoneal dialysis with protective cardiovascular actions |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41231614 https://www.proquest.com/docview/3271933595 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKrVSdxXHtCCFGxtOrQoVtkOzGqhJLSlIqfz13iqmJBSCzZYlnO5e678933EfJgLBdRZDizAOaZiLxgVvOUCUDXSksHYck2YhP90UhNp3ocCm51aKtc-8TGUeeVwxp5L4n7gDVwjPRx_sFQNQpvV4OExjbpJABlsKWrP92wheu4UV4EZ8AZhKY0zOdBEt8r82XvzRsfi1-wZRNjBof_3d0ROQjokj615nBMtoryhOwNw_35KbGTRfVVLMDYSjqrqaFltSreadWI-ThqcM6KAoylyH-MNN2wGE6WIG0JxZItDbwO4COp-9HKStsJifqMTAYvk-dXFlQWmINYr5kxIjFc2thKaaVLhRGAUiBvtAm31uWJ9oiSLJe5T31ulS9cpHIlIghrqojPyU4J-7kklGslDE-cdrCCBAvII6m45U5AFulj1yX368PLwIjxZsKURfVZZ5vj65KL9gtk85ZtIxMQWwGWiqs_vH1N9mPU58U2veSGdDz8wsUt2XWr5axe3DXWAc_RePgNAPLGIg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Troxerutin+is+a+novel+osmotic+agent+for+peritoneal+dialysis+with+protective+cardiovascular+actions&rft.jtitle=Nephrology%2C+dialysis%2C+transplantation&rft.au=Kopytina%2C+Valeria&rft.au=Marchant%2C+Vanessa&rft.au=Rodrigues-Diez%2C+Raquel&rft.au=Pascual-Ant%C3%B3n%2C+Luc%C3%ADa&rft.date=2025-11-13&rft.issn=1460-2385&rft.eissn=1460-2385&rft_id=info:doi/10.1093%2Fndt%2Fgfaf249&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2385&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2385&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2385&client=summon |